RAPT Therapeutics Inc RAPT.OQ RAPT.O is expected to show no change in quarterly revenue when it reports results on August 6 (estimated) for the period ending June 30 2025
LSEG's mean analyst estimate for RAPT Therapeutics Inc is for a loss of 64 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for RAPT Therapeutics Inc is $27.00, about 61.1% above its last closing price of $10.49
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | -1.09 | -1.08 | -0.64 | Beat | 40.7 |
Dec. 31 2025 | -2.50 | -2.98 | -9.12 | Missed | -206.5 |
Sep. 30 2024 | -4.57 | -4.51 | -3.76 | Beat | 16.7 |
Jun. 30 2024 | -5.78 | -5.76 | -5.68 | Beat | 1.4 |
Mar. 31 2024 | -6.41 | -6.47 | -6.32 | Beat | 2.3 |
Dec. 31 2023 | -6.86 | -6.87 | -6.40 | Beat | 6.8 |
Sep. 30 2023 | -5.99 | -6.03 | -6.56 | Missed | -8.9 |
Jun. 30 2023 | -6.32 | -6.25 | -5.28 | Beat | 15.6 |
This summary was machine generated August 4 at 12:37 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。